Literature DB >> 9713937

Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit.

M Isaka1, Y Yasuda, S Kozuka, Y Miura, T Taniguchi, K Matano, N Goto, K Tochikubo.   

Abstract

For the purpose of changing the immunization procedure of tetanus toxoid from intramuscular or subcutaneous injection, which has been in practice for a long time, to intranasal administration, we examined systemic and mucosal immune responses of mice to aluminium-adsorbed tetanus toxoid (aTT) and aluminium-non-adsorbed tetanus toxoid (nTT) inoculated intranasally with recombinant cholera toxin B subunit (rCTB). Intranasal immunization with aTT induced, at a concentration of 0.5 Lf, high levels of TT-specific serum IgG antibody titres and moderate levels of TT-specific serum IgA antibody titres in the presence and absence of rCTB. Induction of high or moderate levels of mucosal TT-specific IgA antibody responses was observed with and without rCTB in the lung, the nasal cavity, the small and large intestines and the vagina. Generally speaking, the co-administration of aTT and rCTB showed higher mucosal TT-specific IgA antibody titres when compared with the administration of aTT alone. In case of intranasal administration of nTT, the dose of 5 Lf was necessary and stimulated, only in the presence of rCTB (10 micrograms), high levels of tetanus toxoid (TT)-specific serum IgG antibody responses in all mice examined and moderate or slight levels of TT-specific IgA antibody responses in the nasal, pulmonary and small and large intestinal lavages of a few mice. All mice intranasally immunized with aTT alone or nTT and rCTB escaped onset of tetanus. This is the first report concerned with the mucosal adjuvant activity of an aluminium compound. Judging from these results, intranasal administration of aTT with and without rCTB or nTT with rCTB appears to be a very useful means for a vaccination against tetanus with respect to ease, safety, certainty, low cost and no need for an injection needle.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713937     DOI: 10.1016/s0264-410x(98)00066-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice.

Authors:  T Jung; W Kamm; A Breitenbach; K D Hungerer; E Hundt; T Kissel
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

2.  Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen.

Authors:  N K Childers; K L Miller; G Tong; J C Llarena; T Greenway; J T Ulrich; S M Michalek
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Nasal aluminum (oxy)hydroxide enables adsorbed antigens to induce specific systemic and mucosal immune responses.

Authors:  Haiyue Xu; Tinashe B Ruwona; Sachin G Thakkar; Yanping Chen; Mingtao Zeng; Zhengrong Cui
Journal:  Hum Vaccin Immunother       Date:  2017-09-21       Impact factor: 3.452

4.  Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization.

Authors:  X Shen; T Lagergård; Y Yang; M Lindblad; M Fredriksson; J Holmgren
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

5.  Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.

Authors:  Gregory A Price; Michael W Russell; Cynthia Nau Cornelissen
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

6.  Tetanus toxoid-loaded layer-by-layer nanoassemblies for efficient systemic, mucosal, and cellular immunostimulatory response following oral administration.

Authors:  Harshad Harde; Ashish Kumar Agrawal; Sanyog Jain
Journal:  Drug Deliv Transl Res       Date:  2015-10       Impact factor: 4.617

7.  Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine.

Authors:  Sachin G Thakkar; Zachary N Warnken; Riyad F Alzhrani; Solange A Valdes; Abdulaziz M Aldayel; Haiyue Xu; Robert O Williams; Zhengrong Cui
Journal:  J Control Release       Date:  2018-10-16       Impact factor: 9.776

8.  An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants.

Authors:  Kenneth C Bagley; Sayed F Abdelwahab; Robert G Tuskan; George K Lewis
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

9.  Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum.

Authors:  C Grangette; H Müller-Alouf; D Goudercourt; M C Geoffroy; M Turneer; A Mercenier
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

10.  Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway.

Authors:  Kenneth C Bagley; Sayed F Abdelwahab; Robert G Tuskan; Timothy R Fouts; George K Lewis
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.